

# ASX Announcement

7 December 2022

# emyria

myriad data.  
individual care.

## Upcoming Emyria CEO Webinars

**Emyria Limited (ASX: EMD)** (Emyria or the Company), a clinical stage biotech informed by patient experience an tackling unmet needs in neuroscience & mental health, is pleased to invite shareholders to two webinars.

**Wednesday 07 December**

12:00 pm AEDT

**“THE INSIDER:  
MEET THE CEOS”**



**Thursday 08 December**

8.00am AEST

**“PLANET MICROCAP  
SHOWCASE: VIRTUAL 2022”**

**Emyria’s Managing Director Dr, Michael Winlo** will discuss the latest updates on Emyria’s clinical stage drug development programs and research, including the recently approved Phase 3 clinical trial of EMD-RX5 and the launch of their US-based preclinical activities for both the CBD and MDMA inspired programs. The presentation deck “ Company Update is available now eon the Emyria website. <https://emyria.com/for-investors/>

### EVENT DETAILS - “THE INSIDER: MEET THE CEOS”

**WEBINAR PRESENTER** Emyria’s Managing Director, Dr. Michael Winlo

**DATE** Wednesday 07 December

**TIME** 12:00pm Sydney time (AEDT)

**WHERE** Webinar - details to be provided upon registration

**TO REGISTER**, please click on the link

<https://reachmarkets.com.au/the-insider-mtc/>

---

### EVENT DETAILS - “PLANET MICROCAP SHOWCASE: VIRTUAL 2022”

**WEBINAR PRESENTER** Emyria’s Managing Director, Dr. Michael Winlo

**DATE** Thursday 08 December

**TIME** 8.00 am Sydney time (AEDT)

**WHERE** Webinar - details to be provided upon registration

**TO REGISTER**, please click on the link

<https://www.webcaster4.com/Webcast/Page/2937/47234>

# emyria

## ABOUT EMYRIA | [emyria.com](https://emyria.com)

**Emyria Limited** is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes via:

- **Drug Development:** Emyria has developed an Ultra-Pure cannabinoid platform that can support the registration of multiple proprietary dose forms. Emyria's first dose form, EMD-RX5 is in Phase 3 trials
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

### EMYRIA'S INTERACTIVE INVESTOR HUB [investorhub.emyria.com](https://investorhub.emyria.com)

Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

*This announcement has been approved and authorised for release by the CEO.*

## FOR FURTHER INFORMATION

**Dr. Michael Winlo**  
**Managing Director**  
**+61 (0) 8 6559 2800**  
[mwinlo@emyria.com](mailto:mwinlo@emyria.com)

**Lexi O'Halloran**  
**Investor Relations**  
**+61 (0) 404 577 076**  
[investors@emyria.com](mailto:investors@emyria.com)

**Andrew Williams**  
**Media Relations**  
**+61 (0) 416 583 672**  
[awilliams@emyria.com](mailto:awilliams@emyria.com)

## CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.